Antitumor activity of anti-type IV collagenase monoclonal antibody and its lidamycin conjugate against colon carcinoma

Figure 1 Immunohistochemical staining of mAb 3G11 in human colon carcinoma section. A: Colon carcinoma (100×, the bar represents 400 μm in length.); B: the same case of A (400×, the bar represents 100 μm in length.); C (100×) and D (400×): another case of typical colon adenocarcinoma.

Figure 2 Immunohistochemical intensity of mAb 3G11 in various cases of human colorectal carcinoma assessed by image analysis and semiquantitative scoring.

Figure 3 Immunological property of mAb 3G11 by Western blot analysis. Lane 1: human colon cancer HT-29 cell lysate; Lane 2: human fibrosarcoma HT-1080 cell lysate; Lane 3: human breast cancer tissue lysate.

Figure 4 Gelatin-zymography assay of HT-29 cells after treatment with mAb 3G11 at different concentrations.

Figure 5 Immunoreactivity of 3G11(A) and 3G11-LDM (B) with type IV collagenase and various cancer cells in ELISA.

Figure 6 Cytotoxicity of LDM to human colon carcinoma HT-29 cells in comparison to ADM and MMC (A) and 3G11-LDM (B).